Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

P. Jansa, S. Heller, M. Svoboda, M. Pad'our, D. Ambrož, V. Dytrych, M. Širanec, T. Kovárník, M. Felšőci, M. Hutyra, A. Linhart, J. Lindner, M. Aschermann,

. 2020 ; 9 (11) : . [pub] 20201109

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001797

Grantová podpora
Progres Q38/LF1 Univerzita Karlova v Praze

Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001797
003      
CZ-PrNML
005      
20210126092746.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm9113608 $2 doi
035    __
$a (PubMed)33182415
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Jansa, Pavel $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
245    10
$a Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. / $c P. Jansa, S. Heller, M. Svoboda, M. Pad'our, D. Ambrož, V. Dytrych, M. Širanec, T. Kovárník, M. Felšőci, M. Hutyra, A. Linhart, J. Lindner, M. Aschermann,
520    9_
$a Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Heller, Samuel $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Svoboda, Michal $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Pad'our, Michal $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Ambrož, David $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Dytrych, Vladimír $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Širanec, Michal $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Kovárník, Tomáš $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Felšőci, Marián $u Department of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Hutyra, Martin $u Department of Internal Medicine I-Cardiology, University Hospital, 779 00 Olomouc, Czech Republic.
700    1_
$a Linhart, Aleš $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Lindner, Jaroslav $u 2nd Department of Surgery-Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Aschermann, Michael $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 9, č. 11 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33182415 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092741 $b ABA008
999    __
$a ind $b bmc $g 1614018 $s 1122081
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 11 $e 20201109 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a Progres Q38/LF1 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace